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Objective: Unstable carotid plaques, characterized by increased levels of macrophages and T lymphocytes, have high
emboligenic potential and carry a risk for producing cerebral ischemic events. It has been suggested that plaque instability
may be mediated by the family of metalloproteinases (MMPs). The purpose of this study was to analyze the relationship
between concentrations of MMP-2 and MMP-9 and unstable carotid plaques, presence of macrophages and T-
lymphocytes in the plaques, and neurologic symptoms, to establish additional risk markers in patients with greater than
70% carotid artery stenosis. This was a cross-sectional study carried out in a referral center and institutional practice in
hospitalized patients.
Methods: The study included 40 patients with carotid artery stenosis treated with carotid endarterectomy. Of these
patients, 67.5% had experienced a previous neurologic event and 32.5% exhibited no symptoms. MMP-2 and MMP-9
levels were determined with enzyme-linked immunosorbent assay 48 hours before surgery. Histopathologic analysis
(stable or unstable) and immunohistochemistry (macrophage count, T lymphocytes, activated T lymphocytes) were
carried out on the plaques.
Results: Mean MMP-2 and MMP-9 serum concentrations in the population studied were 1138.27 326.08 ng/mL and
1026.10  412.90 ng/mL, respectively. MMP-2 levels were significantly higher in patients with symptoms compared
with patients without symptoms (1247.30  276.80 ng/mL vs 911.80  311.84 ng/mL; P  .001). MMP-9 was also
significantly higher in the symptomatic group (1026.10  412.90 ng/mL vs 377.84  164.08 ng/mL; P  .001) and
in patients with unstable plaques compared with those with stable plaques (1006.98  447.09 ng/mL vs 496.16 
292.78 ng/mL; P  .001). In addition, we found a strong association between elevated MMP-9 concentration and
presence of macrophages in plaque (Spearman rho, 0.45; P  .004). At logistic regression analysis, variables that best
predicted the presence of unstable plaque were a previous neurologic event and MMP-9 level greater than 607 ng/mL
(sensitivity, 96%; specificity, 92%; negative predictive value, 94.7%; positive predictive value, 93%).
Conclusion: Elevated MMP-9 concentration is associated with carotid plaque instability and the presence of macrophages,
factors that indicate increased risk for a neurological event. Determination of this gelatinase may enable identification of
high-risk subgroups of patients with carotid artery stenosis. ( J Vasc Surg 2004;40:469-75.)Formation of atherosclerotic plaque is a dynamic pro-
cess that involves various phenomena, such as macrophage
and lymphocyte migration, proliferation of smooth muscle
cells, neovascularization, and repair and remodeling of the
extracellular matrix. Recent studies have suggested that the
different phases of atherosclerosis may be mediated by the
family of metalloproteinases (MMPs),1,2 zinc-dependent
physiologic regulators of the extracellular matrix. Although
it is not completely certain how MMP production is in-
duced by the extracellular matrix, these gelatinases are
necessary for infiltration of monocytes and T lymphocytes
to occur in the subendothelial spaces. Activated endothelial
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doi:10.1016/j.jvs.2004.06.023cells express adhesion molecules, such as vascular cell adhe-
sion molecule–1, which promote infiltration of circulating
monocytes and T lymphocytes. Adhesion of these cells to
the endothelial cells could induce production of MMP-2
(72 kD, gelatinase A), which facilitates breakdown of the
extracellular matrix.3 Furthermore, contact with type I
collagen and laminin in the matrix increases expression of
MMP-9 (92 kD, gelatinase B), and interleukin-1 secretion
can activate pro-MMP-2 and pro-MMP-9 produced by
smooth muscle cells, which could lead to endothelial dis-
ruption or intraplaque hemorrhage.
There is evidence4,5 that unstable carotid plaques, that
is, those with ulceration or recent intraplaque hemorrhage,
are significantly more prevalent in patients with a history of
ischemic neurologic symptoms due to microembolism sec-
ondary to plaque dislodgment, and it seems feasible that
MMPs could be implicated in the process, leading to
plaque instability.
The purpose of this study was to determine the levels of
MMP-2 and MMP-9 in a population of candidates for
carotid surgery with greater than 70% carotid artery steno-469
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of neurologic symptoms, carotid plaque anatomy (stable or
unstable), and carotid plaque cell types related to inflam-
mation (macrophages, T lymphocytes, activated T lympho-
cytes).
Determination of systemic biologic parameters that
indicate the presence of unstable plaques could be a useful
diagnostic indicator for selection of high-risk cohorts in
patients with stenosis of the extracranial internal carotid
artery.
PATIENTS AND METHODS
Patients. Between September 2001 and April 2002,
52 patients with greater than 70% carotid artery stenosis
were admitted to our center for carotid thromboendarter-
ectomy. None of these patients had gastric, hepatic, or
colonic neoplasms, rheumatoid arthritis, or comorbid con-
ditions that can increase MMP expression. Local ethical
committee approval was obtained for the procurement of
specimens, and all patients gave full informed consent for
participation in the study. The protocol we used for later
data analysis was as follows: collection of clinical and para-
clinical data, blood sample collection for MMP quantifica-
tion, performance of carotid surgery, and preservation of
carotid plaques for histologic analysis and immunohisto-
chemistry. In 7 patients plaque processing was inadequate,
and in 5 patients blood sample volume was insufficient for
MMP determination. A final total of 40 patients were
included in the study.
The study patients were 34 men and 6 women, with
ages ranging from 48 to 83 years (mean, 65.1  10.1
years). Twenty-seven patients had experienced a previous
neurologic event, and 13 patients had no symptoms. In
addition to standard epidemiologic variables (age, sex), the
following classic cardiovascular risk factors were recorded:
hypertension, defined as systolic blood pressure 140 mm
Hg or greater or diastolic blood pressure 90 mm Hg or
greater, or current use of antihypertensive medication;
diabetes mellitus, defined as a glycosylated hemoglobin A1c
concentration greater than 5.8% or current use of hypogly-
cemic agents; hypercholesterolemia, defined as a total cho-
lesterol concentration 220 mg/dL or greater or current use
of cholesterol-lowering agents; and smoker, defined as
current smoking or cessation of smoking less than 1 month
before entering the study. Furthermore, we investigated
the presence of concomitant cardiovascular disease, includ-
ing peripheral vascular disease and ischemic heart disease,
treatment with antithrombotic agents and lipid-lowering
drugs, and interval between the neurologic event and blood
collection. We followed the North American Symptomatic
Carotid Endarterectomy Trial criteria6 to classify the pa-
tients as neurologically symptomatic or asymptomatic for
the study. Degree of carotid stenosis was determined with
Doppler ultrasound scanning (Philips SD800) of the supra-
aortic trunks, and with brain angiography in selected pa-
tients,7 including those with greater than 70% stenosis on
one side and greater than 50% stenosis on the other side,with contralateral occlusion or with inconclusive findings
on the Doppler ultrasound scan. The brain parenchyma was
studied with computed tomography in the first cases in-
cluded in the protocol (n  32), and with magnetic reso-
nance imaging in later cases (n  8).
MMP-9 and MMP-2 determinations. Twenty-four
hours before surgery, peripheral blood samples were col-
lected in tubes containing ethylenediamine tetraacetic acid
(EDTA). After centrifugation the serum was siphoned into
freezing vials, snap-frozen in liquid nitrogen, and stored at
80°C. MMP-2 and MMP-9 levels were determined with
a commercially available enzyme-linked immunosorbent
assay (ELISA), using Biotrak assay systems (Amersham) for
MMP-2 and Quantikine (R&D Systems) for MMP-9, val-
idated for use with human serum. ELISAs were performed
according to the manufacturers’ instructions. Normal ref-
erence values, provided by the manufacturers and validated
by our laboratory in samples from 37 healthy volunteers,
for MMP-2 were mean, 633 ng/mL (range, 470-800
ng/mL), and for MMP-9 were mean, 436 ng/mL (range,
169-705 ng/mL). Mean intra-assay coefficients of varia-
tion for the method were 2.9% for MMP-9 and 5.4% for
MMP-2.
Histopathologic analysis. Carotid endarterectomy
was performed in a conventional series of patients with
conventional surgical techniques. In brief, the carotid ar-
tery was incised, and the plaque was removed from within
the lumen as a single specimen. For histopathologic analysis
the surgical specimen was fixed in 10% formalin, decalcified
with EDTA (Surgipath Medical Industries) over 4 hours,
cut transversally in 2-mm blocks, processed, and embedded
in paraffin. The blocks were sectioned at 4 m, and were
stained with hematoxylin-eosin, van Gieson stain for elastic
fibers, and Masson trichrome stain. After the specimens
were prepared for histologic analysis they were examined
with an optic microscope (Dialux 20EB; Leitz) by a pathol-
ogist blinded to MMP levels and to the presence or absence
of neurologic symptoms.
Morphologic characteristics of the carotid plaques were
established according to the classification of the American
Heart Association.8 All plaques were graded as type V or VI
(advanced lesions) with this classification, defined as fol-
lows: type V, fibrous or stable, characterized by fibrous
conjunctive tissue together with extracellular lipids and
laminated acellular collagen, with no evidence of endothe-
lial disruption; and type VI, complicated or unstable, char-
acterized by ulceration (disruption of the endothelial sur-
face) or recent intraplaque hemorrhage consisting of diffuse
blood (polymorphonuclear infiltrate accompanying intact
red blood cells) in the subendothelial space.
Immunohistochemistry. For immunohistochemistry
of the tissue, the thin paraffin-embedded sections were
deparaffinized in xylene, rehydrated through graded alco-
hols, and preincubated in 10% hydrogen peroxide for 10
minutes. Antigen unmasking was performed at high tem-
perature and pressure. The samples were then incubated
with specific antibodies for macrophages, T lymphocytes,
and activated T lymphocytes for 60 minutes at room tem-
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nal for the macrophages (CD68) and activated T lympho-
cytes (HLA-DR), and polyclonal for the T lymphocytes
(CD3). Subsequently, samples were incubated with biotin-
labeled secondary antibodies (Dako Duet; DAKO). Diami-
nobenzidine was used for development. Finally, the blocks
were stained with hematoxylin-eosin for contrast, and were
examined with an optic microscope. Differential cell count
was carried out with a standard morphometry method:
random choice of 10 fields for each preparation, and cell
count for each type of cell in each field. Results are ex-
pressed as number of cells per 10 fields.
Statistical analysis. Statistical analysis of the data was
performed with the SPSS for Windows, version 10.0. Cat-
egorical variables are described in frequencies, because they
followed a normal distribution, with the mean as the central
measurement and the standard deviation as the measure of
dispersion. Variables with a non-normal distribution are
expressed in median and range. Associations were consid-
ered statistically significant at P .05. The 2 test was used
to establish associations among categorical variables, and
the Mann-Whitney U nonparametric test for variables that
did not follow a normal distribution. Comparisons between
quantitative variables were performed with the Spearman
correlation coefficient. A receiver operator characteristic
curve was used to establish the value for macrophage num-
ber associated with unstable plaque. Multivariate analysis
was carried out by creating a logistic regression model with
the forward stepwise method.
RESULTS
The prevalence of epidemiologic variables in neurolog-
ically symptomatic and asymptomatic patients is repre-
sented in Table I. In the symptomatic group (n  27), 17
patients (62.9%) had a transient ischemic attack (7 (41.1%)
retinal, 10 (58.8%) hemispheric) and 10 patients (37%) had
stroke. Doppler ultrasound scanning of the supra-aortic
trunk was performed in all patients to establish the degree
Table I. Clinical and epidemiologic characteristics of stud
Symptomatic (n  2
n
Age (y; mean  SD) 65.5 11
Male gender 23
Body mass index
Mean 24
Range 19–39
Hypertension 11
Smoker 18
Hypercholesterolemia 13
Diabetes mellitus 11
Peripheral vascular disease 16
Ischemic heart disease 10
Antithrombotic agents 11
Lipid-lowering drugs 10
NS, Not significant.of stenosis, and in 15 patients (37.5%) cerebral angiography
was also indicated. To study the brain parenchyma, com-
puted tomography was performed in 32 patients (80%) and
MRI in 8 patients (20%). Of these studies, 57.5% were
interpreted as normal, 12.5% of patients exhibited cortical
atrophy, and 30 patients had ischemic areas corresponding
to the region of study. No clinically silent infarctions were
detected.
At histologic analysis 62.5% of plaques were classified as
unstable and 37.5% as stable. Regarding differential cell
count, in both types of plaques the most frequently en-
countered cells were macrophages, followed by T lympho-
cytes and activated T lymphocytes. A median of 17 macro-
phages per 10 fields (range, 2-45) was found in unstable
plaques, and 5 macrophages per 10 fields (range, 2-10) in
stable plaques. T lymphocyte count was 3 cells per 10 fields
(range, 0-7) in unstable plaques, and 1 cell per 10 fields
(range, 0-5) in stable plaques. Activated T lymphocytes
presented a median of 2 cells per 10 fields (range, 0-5) in
unstable plaques, and 0 cells per 10 fields (range, 0-2) in
stable plaques. Differences between the 2 groups were
significant (P  .001). Unstable plaques were significantly
associated with the presence of neurologic symptoms (P 
.01).
MMP-2 neurologic symptoms, plaque types, and
cells. Mean ( SD) MMP-2 concentration in the total
series was 1138.27  326.08 ng/mL, with significant
differences as compared with the reference value (P 
.001). MMP-2 was higher (1247.30 276.80 ng/mL) in
patients with a previous neurologic event than in patients
with no symptoms (911.80 311.84 ng/mL) (P0.001).
There were no differences in MMP-2 levels in the analyses
performed within 1 month of the neurologic event and
those performed later. Mean MMP-2 level was 1209.47 
244.38 ng/mL in patients with plaques considered unsta-
ble, and 1019.60  411.91 ng/mL in patients with stable
plaques (P .07; Fig 1). There was no association between
pulation
Asymptomatic (n  13)
Pn %
64.4  8.2 NS
11 84.6 NS
23 NS
1–28
7 53.8 NS
9 69.2 NS
4 30.7 NS
6 46.1 NS
8 61.5 NS
7 53.8 NS
8 61.5 NS
6 61.5 NSy po
7)
%
85.1
40.7
66.6
48.1
40.7
59.2
37
40.7
37
JOURNAL OF VASCULAR SURGERY
September 2004472 Alvarez et alincreased MMP-2 concentration and any of the cell types
identified at immunohistochemistry.
MMP-9 neurologic symptoms, plaque types, and
cells. MMP-9 concentration in the entire study cohort was
1026.10  412.90 ng/mL, with significant differences as
compared with the reference value (P .001). There was a
clear association between increased MMP-9 concentration
and a previous neurologic event. Mean MMP-9 values in
Fig 1. MMP-2 concentration relative to plaque structure (stable
or unstable) and neurologic events.
Fig 2. MMP-9 concentration relative to plaque structure (stable
or unstable) and neurologic events.patients with symptomatic disease was 1026.10  412.90
ng/mL, versus 377.84  164.08 ng/mL in patients with
asymptomatic disease (P  .001). In patients in whom
MMPs were determined and plaques were examined within
the first month after the neurologic event, MMP-9 levels
were significantly higher than in patients examined after the
first month: 1213.4  390.4 ng/mL versus 832.55 
389.1 ng/mL (P  .01). We found a strong association
between unstable plaque and high MMP-9 levels: 1006.98
 447.09 ng/mL in patients with unstable plaques and
496.16  292.78 ng/mL in patients with stable plaques
(P  .001; Fig 2).
Regarding cell types, we found that the greater the
number of macrophages in the plaques the higher the levels
of MMP-9 (Spearman rho 0.45; P  .004; Fig 3). There
were no differences in number of macrophages or lympho-
cytes between plaques analyzed within 1 month after the
event and those analyzed later.
There were no significant differences between the var-
ious cardiovascular risk factors and MMP overexpression or
between drug use (antithrombotic or lipid-lowering
agents) and MMP levels (Table II).
The cutoff point for MMP-9 that best predicted the
presence of unstable plaque was 607 ng/mL (odds ratio
[OR], 19.20; 95% confidence interval [CI], 3.91-94.18; P
 .001), with sensitivity 96%, specificity 92%, positive
predictive value 93%, and negative predictive value 94.7%.
After logistic regression the presence of neurologic symp-
toms was the only variable that remained in the model as an
independent predictor of unstable plaque (OR, 40.625;
95% CI, 6.55-251.96; P  .001; Table III).
Fig 3. MMP-9 concentration relative to number of macrophages
in plaque.
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The results of this study uphold the hypothesis that
MMPs are implicated in the mechanisms that cause desta-
bilization of atherosclerotic plaque and in the pathogenesis
of cerebral ischemic events, through interactions with im-
mune system cells, macrophages, and T lymphocytes. Sev-
eral studies have related elevated levels of these gelatinases
with atherosclerotic plaque instability. Kai et al9 deter-
mined serum MMP-2 and plasma MMP-9 concentrations
in 33 patients with acute coronary syndrome and in 17
healthy control subjects, and found that patients with un-
stable angina or acute myocardial infarction had MMP-2
levels up to twice as high and MMP-9 levels 2-fold or 3-fold
higher than those in healthy control subjects. Along this
same line, Inoue et al10 reported elevated MMP-1 and
MMP-3 concentrations in patients with unstable angina or
acute myocardial infarction compared with healthy subjects
or patients with stable exertional angina. More recently,
Morgan et al11 studied levels of MMP-1, MMP-3, MMP-7,
MMP-9, and MMP-12 in relation to carotid plaque mor-
phologic characteristics and neurologic symptoms, and
concluded that MMP-1 and MMP-12 determine athero-
sclerotic plaque stability. With regard to the mechanisms
implicated in the production of MMPs, in addition to
monocytes and T lymphocytes some authors have demon-
strated platelet involvement. Fernandez-Patron et al12
identified MMP-2 and MMP-9 in human platelets, and
suggested that the MMP-2 or MMP-9 system may have an
important role in regulation of platelet-platelet and plate-
let-vessel wall interactions. Furthermore, in a study exam-
Table II. Association between cardiovascular risk factors,
and MMP-9 concentrations
Unstable (n  25)
n
Age (y; mean  SD) 65.8  11
Male gender 23
Body mass index
Mean 24
Range 19–39
Hypertension 9
Smoker 16
Hypercholesterolemia 13
Diabetes mellitus 10
Peripheral vascular disease 14
Ischemic heart disease 10
Antithrombotic agents 10
Lipid-lowering drugs 9
Neurologic event 24
Lesion CT or MRI 9
MMP-2 (mean  SD) 1209.5  244.4
MMP-9 (mean  SD) 1007.0  447.1
Macrophages
Median 17
Range 2–45
T lymphocytes
Median 3
Range 0–7
MMP, Matrix metalloproteinase; CT, computed tomography; MRI, magneining the cellular interactions occurring in plaque destabi-
lization, Galt et al13 found that monocyte interaction with
collagen and platelets is required for these leukocytes to
synthesize MMP-9 and that the interactions are produced
particularly in areas of the vessel where inflammatory phe-
nomena develop in response to injury.
We found significantly higher MMP-9 concentrations
in patients with previous neurologic symptoms and unsta-
ble plaques as determined at histologic analysis, and a
strong association between MMP-9 overexpression and the
presence of macrophages in the plaques. In contrast,
MMP-2 concentrations were only slightly higher in the
symptomatic group than in the asymptomatic group, but
there was no association with any of the cell types studied.
The increased MMP-9 concentration in these patients
could result from extracellular matrix breakdown and repair
activity in response to endothelial rupture or interplaque
hemorrhage (in response to plaque instability), or it could
be produced with cerebral ischemia. However, analysis of
ischemic lesions in the brain parenchyma and MMP-9
ologic events, plaque structure, cell type, and MMP-2
Stable (n  15)
Pn %
64.4  8.5 NS
.1 11 84.6 NS
23 NS
1–28
6 9 60 NS
4 11 73.3 NS
2 4 26.7 NS
0 7 46.7 NS
6 10 66.7 NS
0 7 46.7 NS
0 9 60 NS
6 7 46.7 NS
6 3 20 .001
6 3 20 NS
1019.6  411.9 NS
496.2 292.8 .001
5 0.001
2–10
1 .001
0–5
onance imaging; NS, not significant.
Table III. Factors associated with unstable plaque in
logistic regression model
OR 95% CI P
.001
Clinical 40.625 6.55–251.96
MMP-9 19.20 3.91–94.18 .001
MMP, Matrix metalloproteinase; OR, odds ratio; CI, confidence interval.neur
%
85
3
6
5
4
5
4
4
3
9
3
tic res
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the region of study in 30% of patients, and unstable plaques
in 62.5% of patients, with associations between MMP-9
overexpression and presence of unstable plaques but not
areas of cerebral ischemia. Moreover, the interval between
cerebral infarction and MMP determination in the present
study was 6.54  3.44 weeks. In patients with MMP
determinations and plaque analysis within the first 30 days
after the ischemic event, MMP-9 levels were significantly
higher than in those studied after 30 days. With regard to
the presence of macrophages and lymphocytes, there were
no such time-related differences.
This leads us to believe that the increased levels of this
gelatinase were due to plaque instability and not to cerebral
injury. Along this line, works such as those by Loftus et
al14,15 have demonstrated that there is a local increase in
active MMP-9 concentration in most unstable carotid
plaques when these are defined by the presence of focal
neurologic symptoms and cerebral microembolism de-
tected at transcranial Doppler scanning. Recently Molloy et
al16 studied MMP-9 levels in patients undergoing carotid
endarterectomy in whom microembolisms were detected
with transcranial Doppler scanning during surgery. The
authors reported that patients with microembolisms had
higher MMP-9 levels 48 hours later, and attributed this
elevation to the cerebral injury.
Some interesting work has been done to establish the
role of MMPs in cerebral ischemic events. Using an animal
model, Rosemberg et al17 demonstrated that MMP-9 ac-
tivity increases from the first 12 hours after the ischemic
event up to the fifth day afterward, whereas MMP-2 in-
creases after the fifth day post-ischemia. A necropsy study
performed by Clark et al18 found maximum MMP-9 activ-
ity between the second and fourth days after stroke, with
subsequent decreases, whereas MMP-2 activity persisted up
to 4 months after the event, with minimum overexpression
in the initial phases. In the histologic analysis of plaques
classified as unstable, that is, those with ulceration or recent
intraplaque hemorrhage, we found a significantly elevated
number of cells implicated in cellular immunity (macro-
phages, T lymphocytes, activated T lymphocytes), as com-
pared with findings in stable plaques. There were no differ-
ences in cell numbers in patients examined within the first
month after the event and those studied later. Macrophages
predominated among the 3 cell types studied, followed by
T lymphocytes and activated T lymphocytes. These results
support the concept that macrophages are present in all
phases of the atherosclerotic process, whereas lymphocytes,
activated or not, appear in more advanced phases of the
lesions. Studies such as those by Carr et al4 and Moreno et
al5 support these findings. Carr et al4 concluded that rup-
ture of the fibrous cap in carotid artery lesions is associated
with increased numbers of macrophages and T lympho-
cytes, which are in an activated state. The activated inflam-
matory cells could release cytokines or MMPs, which may
be responsible for loss of the fibrous cap. Thus inflamma-
tion appears to have a role in the pathogenesis of the
neurologic symptoms associated with carotid artery steno-sis. In a study involving coronary plaques, Moreno et al5
reported that macrophage-rich areas are more frequently
found in patients with unstable angina and non-Q-wave
myocardial infarction. This suggests that macrophages are a
marker of unstable atherosclerotic plaques and may have a
significant role in the pathophysiologic findings in acute
coronary syndromes.
The positive correlation we found between the pres-
ence of macrophages and MMP-9 overexpression may be
attributed to the fact that these cells are potent MMP-9
producers.19 It seems that the inflammatory phenomena
occurring in atherosclerosis could increase MMP expres-
sion in the extracellular matrix through cytokine secretion
and the presence of macrophages, cells that are infrequently
found in normal arterial tissue but that accumulate in areas
of the plaque prone to complications.
In the present study, increased MMP-2 levels were
found in both symptomatic and asymptomatic disease, but
there was no relationship between MMP-2 overexpression
and carotid plaque architecture. The finding of MMP-2
overexpression in asymptomatic disease may have to do
with the inclusion of patients who had a neurologic event
more than 6 months before surgery. MMP-2 increases have
been known to persist up to 4 months after the neurologic
event.18 It may be that there was still some residual MMP-2
overexpression in these patients, even though more than 4
months had elapsed.
No correlations were found between elevated MMP-2
levels and unstable plaque or between elevated MMP-2 and
the presence of macrophages or T lymphocytes in the
plaque. These data lead us to think that the increased levels
of this gelatinase in patients with symptomatic disease is
probably more related to cerebral injury than to carotid
plaque destabilization, in contrast to MMP-9.
It has been proposed that statins can prevent the in-
flammatory activity that occurs in plaque destabilization. In
our series, however, we found no significant differences
between patients taking statins and those who did not
receive this medication, either in the characteristics of the
plaques or in their macrophages or T lymphocyte content.
Blankenberg et al20 suggested that MMP-9 can be
considered a new predictive factor for cardiovascular mor-
tality. In a prospective study including 1127 patients with
documented coronary disease, these authors measured
basal MMP-9 concentrations and determined MMP-9 ge-
notypes. After a mean follow-up of 4.1 years, they observed
that the patients who died of a cardiovascular cause had
significantly higher MMP-9 levels than did those who
survived. The crude hazard risk ratio of cardiovascular
death associated with increasing quartiles of MMP-9 was
1.4 (95% CI, 1.2-1.8; P  .0001), and after adjusting for
clinical and therapeutic confounders, it was 1.3 (95% CI,
1.1-1.6; P  .005). The authors concluded that plasma
MMP-9 concentration is a new predictor of cardiovascular
mortality in patients with coronary artery disease. Whether
it provides independent prognostic information, as com-
pared with other inflammatory markers, will also have to be
assessed.
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berg et al20 and other studies, such as those by Loftus et
al,14,15 we mention that the actual reported MMP values in
these studies are much lower than those found in the
present investigation. We believe the reasons for this dis-
crepancy reside in the different methods used for MMP
analysis, and particularly in the different samples analyzed.
These other authors measured MMP in plasma, whereas we
determined the concentrations in serum. Our rationale for
using this sample was to avert variation in the results from
incomplete removal or activation of platelets in plasma.
Normal MMP values are quite different in plasma and
serum; however, our assays recognized both the active and
latent total enzyme, which may also have contributed to the
difference in the absolute values obtained between the
studies. Nevertheless, the concepts coveyed by the results
were similar in all 4 works.
In line with the results of these authors, we found
elevated MMP-9 in patients with a previous neurologic
ischemic event and unstable plaques, and a positive corre-
lation between levels of this gelatinase and the presence of
macrophages in the plaque. We believe these findings could
have diagnostic and therapeutic implications. Among pa-
tients with more than 70% carotid artery stenosis, increased
plasma MMP-9 levels could indicate the presence of unsta-
ble carotid plaques and identify patients at high risk. Fi-
nally, in the same way that platelets became targets for
therapeutic interventions when their activity in atheroscle-
rosis was elucidated in the 1970s, the implication of mac-
rophages in the inflammatory mechanisms apparently asso-
ciated with atherosclerosis may make them potential
candidates for a therapeutic approach that will reduce their
influence in this disease.
We thank Manuel Quintana, Section of Neurology,
Hospital Universitario Vall d’Hebron, for the statistical
analysis.
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